<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146623</url>
  </required_header>
  <id_info>
    <org_study_id>CODA01-002</org_study_id>
    <nct_id>NCT04146623</nct_id>
  </id_info>
  <brief_title>Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray</brief_title>
  <official_title>A Randomized Double-Blind, Placebo Controlled, Phase I Study of the Safety, Tolerability and Immunogenicity of a Live Attenuated H1N1 Vaccine in Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Codagenix, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Codagenix, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to assess the safety, tolerability, and immunogenicity of the&#xD;
      live-attenuated CodaVax-H1N1 influenza vaccine as compared to normal saline placebo both&#xD;
      administered via intranasal spray to healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Actual">November 11, 2020</completion_date>
  <primary_completion_date type="Actual">October 11, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reactions to vaccine</measure>
    <time_frame>6 days</time_frame>
    <description>Number of solicited local and systemic reactions for CodaVax-H1N1 and placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>30 days</time_frame>
    <description>Number of subjects with AEs for CodaVax-H1N1 and placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events (SAEs)</measure>
    <time_frame>180 days</time_frame>
    <description>Number of subjects with SAEs for CodaVax-H1N1 and placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HAI antibody titers against A/California/07/2009</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>Geometric mean titers (GMT) of anti-A/California/07/2009 (H1N1) antibodies (Hemagglutination inhibition, HAI) for each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in HAI titer against A/California/07/2009</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>Geometric mean fold increase (GMFI) of anti-A/California/07/2009 (H1N1) HAI serum antibodies for each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI sero-response</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>The proportion of participants, regardless of sero-status, within each treatment arm who experience an H1N1 CA/07/2009 specific sero-response post-dose. Sero-response is defined as a ≥4-fold rise in HAI titer from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IgG response</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>The proportion of participants within each treatment arm with a greater or equal to 2-fold rise in serum lgG antibody responses to whole virus CA/07/2009 by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in serum IgG</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>Geometric mean fold increase (GMFI) within each treatment arm in serum lgG antibody responses to whole virus CA/07/2009 by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IgA response</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>The proportion of participants within each treatment arm with a greater or equal to 2-fold rise in serum lgA antibody responses to whole virus CA/07/2009 by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in serum IgA</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>Geometric mean fold increase (GMFI) within each treatment arm in serum lgA antibody responses to whole virus CA/07/2009 by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary IgA Response</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>The proportion of participants within each treatment arm with a greater or equal to 2-fold rise in salivary lgA antibody responses to whole virus CA/07/2009 by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in salivary IgA</measure>
    <time_frame>Day 0 and 30</time_frame>
    <description>Geometric mean fold increase (GMFI) within each treatment arm in salivary lgA antibody responses to whole virus CA/07/2009 by ELISA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Normal Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline (0.9%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CodaVax-H1N1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Live-attenuated influenza vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CodaVax-H1N1 influenza vaccine</intervention_name>
    <description>CodaVax-H1N1, a live attenuated vaccine (LAIV) strain based on the A/California/07/2009 (H1N1) influenza virus, administered once intranasally via a sprayer at a dose of 8 x10^5 plaque forming units (PFU).</description>
    <arm_group_label>CodaVax-H1N1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Normal Saline Placebo</intervention_name>
    <description>Saline (0.9%) administered intranasally via sprayer</description>
    <arm_group_label>Normal Saline Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult volunteers, aged 18 to 45 years (at the time of screening) in good general&#xD;
             health in the opinion of the Medical Investigator or delegate, with no significant&#xD;
             medical history and no clinically significant abnormal findings at screening.&#xD;
&#xD;
          2. Participants must use highly effective, double contraception from the Screening Visit&#xD;
             and up to the Follow-up Visit (Day 30).&#xD;
&#xD;
          3. Must be willing to comply with the following conditions to prevent the spread of&#xD;
             Genetically modified organisms (GMO) according the Office of Gene Technology Regulator&#xD;
             (OGTR) Licence (DIR 144):&#xD;
&#xD;
               1. Hygiene measures intended to prevent interpersonal transmission of study drug&#xD;
                  must be implemented, including but not limited to frequent handwashing with soap&#xD;
                  or hand disinfectant, respiratory hygiene and cough etiquette within 7 days&#xD;
                  following vaccination&#xD;
&#xD;
               2. Blood, tissue or organs must not be donated within 7 days of vaccination&#xD;
&#xD;
               3. Severely immunosuppressed persons who require a protective environment are not to&#xD;
                  be cared for by the participant within 7 days of vaccination&#xD;
&#xD;
               4. Contact is not to be made with severely immunosuppressed persons who require a&#xD;
                  protective environment within 7 days of vaccination&#xD;
&#xD;
               5. All tissues and materials used to collect respiratory secretions are to be sealed&#xD;
                  in a primary container and placed within a secondary container so that it is not&#xD;
                  accessible to children or animals for 7 days until it is returned to the study&#xD;
                  site for disposal, for 7 days within vaccination&#xD;
&#xD;
          4. Contact is not to be made with infants &lt;6 months of age within 7 days of vaccination.&#xD;
&#xD;
          5. Adequate venous access in the left or right arms to allow collection of a number of&#xD;
             blood samples.&#xD;
&#xD;
          6. Must be sero-susceptible ≤10 hemagglutination inhibition (HAI) titre to CA/07/2009&#xD;
             Influenza virus (pre-screen).&#xD;
&#xD;
          7. Laboratory Testing:&#xD;
&#xD;
               1. Full blood examination and biochemistry within the laboratory defined normal&#xD;
                  range unless deemed not clinically significant by the investigator, however a&#xD;
                  small drop below the normal range for Absolute Neutrophil Count (ANC) may be&#xD;
                  acceptable as per investigator discretion;&#xD;
&#xD;
               2. Urinalysis: Negative urine glucose, negative or trace urine protein, negative or&#xD;
                  trace urine hemoglobin (if trace hemoglobin is present on dipstick, a microscopic&#xD;
                  urinalysis within institutional range)&#xD;
&#xD;
          8. Able to communicate effectively with study personnel and considered reliable, willing&#xD;
             and cooperative in terms of compliance with the protocol requirements&#xD;
&#xD;
          9. Participant does not intend to start or change an existing physical conditioning&#xD;
             regimen prior to or during the study period&#xD;
&#xD;
         10. Participant has voluntarily given written informed consent to participate in the study&#xD;
             (prior study entry)&#xD;
&#xD;
         11. Participant is available for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Immunodeficiency (including HIV) or autoimmune disorder, or participant is currently&#xD;
             taking drugs (excluding steroids, see exclusion criteria 16) or was undergoing a form&#xD;
             of treatment within 3 months prior to study entry that affects the immune system, or&#xD;
             participant is living with somebody with the same&#xD;
&#xD;
          2. Participant is not to have had Guillain-Barre Syndrome&#xD;
&#xD;
          3. Received blood or blood products in the 3 months prior to screening&#xD;
&#xD;
          4. Received another vaccine within 30 days before screening&#xD;
&#xD;
          5. Received another influenza vaccine from 2016 to present year&#xD;
&#xD;
          6. Participants with plans to travel to the Northern Hemisphere during the Screening&#xD;
             period&#xD;
&#xD;
          7. Participated in another clinical study (involving any investigational product or&#xD;
             device) within 60 days before screening&#xD;
&#xD;
          8. Suffered previous anaphylactic reaction to foods, vaccines, drugs or hymenoptera&#xD;
             stings, or has a history of severe allergic reactions (e.g. clinically severe&#xD;
             urticaria, asthma)&#xD;
&#xD;
          9. Participants with active asthma or a history of childhood asthma which was treated&#xD;
             with corticosteroids.&#xD;
&#xD;
         10. Participants with a known egg allergy&#xD;
&#xD;
         11. If female, pregnant, planning to become pregnant, or lactating, or participants is&#xD;
             living with somebody who is pregnant or lactating.&#xD;
&#xD;
         12. Participant has a history of, or current evidence at the time of screening of abuse of&#xD;
             alcohol or any drug substance, licit or illicit, or current alcohol consumption is &gt; 4&#xD;
             standard drinks (or equivalent) per day&#xD;
&#xD;
         13. History of any psychiatric illness or psychological disorder which may impair the&#xD;
             ability to provide written informed consent or participate in the study&#xD;
&#xD;
         14. Current or history of significant neurological, cardiovascular, pulmonary (including&#xD;
             asthma), hepatic, rheumatic, autoimmune, hematological, metabolic or renal disorder&#xD;
&#xD;
         15. Clinically significant abnormal laboratory value at screening as determined by the&#xD;
             Investigator&#xD;
&#xD;
         16. Known or suspected impairment/alteration of immune function, including: Chronic use of&#xD;
             oral steroids (equivalent to 20 mg/day prednisone ≥12 weeks /≥2 mg/kg body weight /&#xD;
             day prednisone ≥2 weeks) within 60 days prior to Day 0 (use of inhaled, IN, or topical&#xD;
             corticosteroids is allowed, unless used for the management of asthma - see exclusion&#xD;
             criteria 9). Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12&#xD;
             weeks /≥2 mg/kg body weight/day prednisone ≥ 2 weeks) within 60 days prior to Day 0.&#xD;
             Or participant is living with somebody with the same&#xD;
&#xD;
         17. Unusual dietary habits and excessive or unusual vitamin intake likely, in the opinion&#xD;
             of the Investigator, to affect safety parameters&#xD;
&#xD;
         18. Participant is sero-positive to hepatitis C virus or hepatitis B virus.&#xD;
&#xD;
         19. Body temperature (oral) ≥38.0ºC or acute illness within 5 days prior to vaccination&#xD;
&#xD;
         20. Any other significant finding that, in the opinion of the Investigator, would increase&#xD;
             the risk of the individual having an adverse outcome from participating in this study&#xD;
&#xD;
         21. Participant is a member of the team or is related or in a dependent relationship with&#xD;
             a member of the study team, as defined as the Sponsor or study site personnel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Q-Pharm Pty Limited</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>November 28, 2020</last_update_submitted>
  <last_update_submitted_qc>November 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>live-attenuated vaccine</keyword>
  <keyword>influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

